These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 28885037)

  • 21. [Novel insulins].
    Eriksson JG; Laine MK
    Duodecim; 2016; 132(5):447-51. PubMed ID: 27089618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes.
    Orchard TJ; Cariou B; Connelly MA; Otvos JD; Zhang S; Antalis CJ; Ivanyi T; Hoogwerf BJ
    Cardiovasc Diabetol; 2017 Jun; 16(1):73. PubMed ID: 28587667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New Insulins, Biosimilars, and Insulin Therapy.
    Danne T; Heinemann L; Bolinder J
    Diabetes Technol Ther; 2019 Feb; 21(S1):S57-S78. PubMed ID: 30785319
    [No Abstract]   [Full Text] [Related]  

  • 24. Glucose-lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes.
    Derosa G; Franzetti I; Querci F; Romano D; D'Angelo A; Maffioli P
    Diabetes Obes Metab; 2015 Jun; 17(6):554-559. PubMed ID: 25694300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes.
    Ocheltree SM; Hompesch M; Wondmagegnehu ET; Morrow L; Win K; Jacober SJ
    Eur J Endocrinol; 2010 Aug; 163(2):217-23. PubMed ID: 20508081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Will the next generation of basal insulins offer clinical advantages?
    Garber AJ
    Diabetes Obes Metab; 2014 Jun; 16(6):483-91. PubMed ID: 24118819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes.
    Lamb YN; Syed YY
    BioDrugs; 2018 Feb; 32(1):91-98. PubMed ID: 29368288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The advent of biosimilars for the treatment of diabetes: current status and future directions.
    Polimeni G; Trifirò G; Ingrasciotta Y; Caputi AP
    Acta Diabetol; 2015 Jun; 52(3):423-31. PubMed ID: 25990669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel insulins: expanding options in diabetes management.
    Gerich JE
    Am J Med; 2002 Sep; 113(4):308-16. PubMed ID: 12361817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The biosimilar insulin landscape: current developments.
    Lavalle-González FJ; Khatami H
    Postgrad Med; 2014 Oct; 126(6):81-92. PubMed ID: 25414937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus.
    Ilag LL; Deeg MA; Costigan T; Hollander P; Blevins TC; Edelman SV; Konrad RJ; Ortmann RA; Pollom RK; Huster WJ; Zielonka JS; Prince MJ
    Diabetes Obes Metab; 2016 Feb; 18(2):159-68. PubMed ID: 26434665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
    Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
    Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quality Control of Insulins and Biosimilar Insulins: What Do We Know?
    Carter AW; Heinemann L; Klonoff DC;
    J Diabetes Sci Technol; 2016 Jul; 10(4):811-5. PubMed ID: 26989067
    [No Abstract]   [Full Text] [Related]  

  • 34. Interchangeable Insulins - New Pathways for Safe, Effective, Affordable Diabetes Therapy.
    Socal MP; Greene JA
    N Engl J Med; 2020 Mar; 382(11):981-983. PubMed ID: 32160658
    [No Abstract]   [Full Text] [Related]  

  • 35. Reduction in short-acting insulin requirement accompanies improved glycemic control with basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes.
    Rosenstock J; Blevins TC; Bergenstal RM; Morrow LA; Qu Y; Jacober SJ
    J Diabetes; 2016 Jan; 8(1):166-9. PubMed ID: 26278063
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine: SORELLA 2 Study.
    Derwahl KM; Bailey TS; Wernicke-Panten K; Ping L; Pierre S
    Diabetes Technol Ther; 2018 Jan; 20(1):49-58. PubMed ID: 29232162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin therapy in diabetes mellitus: how can the currently available injectable insulins be most prudently and efficaciously utilised?
    Bell DS
    Drugs; 2007; 67(13):1813-27. PubMed ID: 17722952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Biosimilar insulines - new possibilities of diabetes treatment].
    Škrha J
    Vnitr Lek; 2015 Apr; 61(4):301-3. PubMed ID: 25894258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New Insulins, Biosimilars, and Insulin Therapy.
    Danne T; Heinemann L; Bolinder J
    Diabetes Technol Ther; 2020 Feb; 22(S1):S32-S46. PubMed ID: 32069160
    [No Abstract]   [Full Text] [Related]  

  • 40. Reducing mistakes in patient administration of glargine and lispro.
    Schutta MH
    Diabetes Care; 2002 Jun; 25(6):1098-9. PubMed ID: 12032124
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.